---
document_datetime: 2025-12-08 09:49:05
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ebglyss-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ebglyss-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.618658
conversion_datetime: 2025-12-22 11:54:14.173317
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ebglyss

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 08/12/2025                          |                                             | SmPC                             |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000313047                     | finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000249804 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted • C.I.4: Update of sections 4.8, and 5.1 of the SmPC in order to update information on clinical efficacy and the long- term safety based on final results from study J2T-DM-KGAA (ADjoin) listed as a category 3 study in the RMP; this is a long-term study to assess the long-term safety and efficacy of lebrikizumab in patients with moderate- to-severe atopic dermatitis over 100 weeks; | 02/10/2025 | SmPC and Annex II | With this submission, data on long-term safety has been strengthened. Additional information on the long term efficacy and safety of lebrikizumab is provided in the PI: • In adults and adolescents with moderate-to-severe AD treated continuously with lebrikizumab for up to 3 years: study J2T-DM- KGAA (ADjoin) and • In adults and adolescents with moderate-to-severe AD who were not adequately controlled with ciclosporin (also known as cyclosporine) or for whom ciclosporin was not medically advisable: study J2T-AP-KGBQ (Advantage). In ADjoin, a 100-week extension study to assess the long-term safety and efficacy of lebrikizumab for adults and adolescents with moderate-to-severe AD, a total of 1153 participants (including 292 adolescents) were exposed to lebrikizumab. The incidence and severity of TEAEs were similar to those previously reported. ADvantage was a Phase 3 clinical trial to assess the efficacy and safety of lebrikizumab in combination with topical corticosteroids (TCS) up to 52 weeks in adults and adolescents with moderate-to-severe AD who were not adequately controlled with ciclosporin or for whom ciclosporin use was not medically advisable. 331 patients were randomized; from them, 68.4% of patients in the lebrikizumab group |

<div style=\"page-break-after: always\"></div>

|                                          | • C.I.4: Update of section 5.1 of the SmPC in order to update information on clinical efficacy based on final results from study J2T-AP-KGBQ (Advantage); this is a randomised, double-blind, placebo-controlled phase 3 clinical trial to assess the efficacy and safety of lebrikizumab in combination with topical corticosteroids up to 52 weeks in patients with moderate to-severe atopic dermatitis who were not adequately controlled with ciclosporin or non-eligible for cyclosporine. The RMP version 1.2 is approved. In addition, the MAH took the opportunity to introduce changes following PEI linguistic review (clarification of acronyms and QRD updates), and editorial   |            |     |             | and 40.8% in the placebo group achieved EASI 75 at Week 16 (primary endpoint); 42.0% of patients in lebrikizumab group and 24.5% in placebo group achieved IGA 0 or 1 and ≥2-point improvement at week 16, and 49.9% of patients in lebrikizumab group and 29.7% in placebo group achieved ≥4 point improvement in Pruritus NRS from baseline at week 16 (key secondary endpoints). The incidence and severity of TEAEs reported during the induction phase of ADvantage were similar to those reported in previous studies. The nature, incidence and severity of TEAEs reported in ADjoin and ADvantage were similar to those previously reported. For more information, please refer to the Summary of Product Characteristics.   |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000287025    | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 02/10/2025 |     | SmPC and PL | As a result of this variation, section 6.6 of the SmPC is being updated to remove the warm-up period. The Package Leaflet (PL) and IFU has been updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Variation type IA_IN / EMA/VR/0000301550 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 30/09/2025 | N/A |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000291266    | B.II.e.3 Change in test procedure for the immediate packaging of the finished product - B.II.e.3.b Other changes to a test procedure (including replacement or addition) - Accepted                                                                                                                                                                                                                                                                                                                                                        | 27/08/2025   | N/A   |                        |                   |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------------------------|-------------------|
| Variation type IB /                      | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                 | 01/07/2025   | N/A   |                        | EMA/VR/0000278725 |
| Variation type IA_IN / EMA/VR/0000261461 | B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted                                                                                                                                                                                                                                                                                                                                                                   | 10/04/2025   |       | SmPC, Labelling and PL |                   |
| Variation type IB / EMA/VR/0000261559    | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - To update sections 2 and 4.4 of the SmPC and section 2 of the Package Leaflet with the current Excipients Guideline for excipient polysorbate (Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668) - Revision 4). In addition, the MAH took the opportunity to introduce some minor editorial changes in the whole Product Information in all EU | 01/04/2025   |       | SmPC, Labelling and PL |                   |

<div style=\"page-break-after: always\"></div>

|                                          | languages.                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |                                                                                                                                                                                                                                                    |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000253475 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 18/02/2025 | N/A |                                                                                                                                                                                                                                                    |
| Variation type IB / EMA/VR/0000244577    | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted                                                                                                                                                                                                                                                       | 31/01/2025 | N/A |                                                                                                                                                                                                                                                    |
| PSUR / EMA/PSUR/0000248530               | n/a                                                                                                                                                                                                                                                                                                                                                                                                              |            |     | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing lebrikizumab remains unchanged and therefore recommends the maintenance of the marketing authorisation. |